The comparison of two drugs, the new SGLT2 inhibitor with the current sulfonylurea used in the treatment of type 2 DM as an adjunctive therapy to metformin, has shown some promising results. A 3-level dosage titration was performed at weeks 8 and 16 to assess tolerability and observe hypoglycemic events associated with each dosage. The trend of decline in FBS, PLBS and HbA1c values ​​was different for both the SGLT2 inhibitor and the sulfonylurea. The SGLT2 inhibitor group showed a gradual decline in FBS, PLBS and HbA1c values ​​up to week 8 and then had a rapid decrease in these values ​​up to week 24 and also during the maintenance period up to week 60. It was further noted that after week 8, as the dose level increased, efficacy improved with respect to glycemic control, but hypoglycemic events also increased from 3% at week 8 to 7% at week 60. None of the hypoglycemic events noted had random blood sugar levels <60 mg/dl and were promptly treated. Similarly, in the Sulfonylurea group, FBS, PLBS and HbA1c initially decreased until week 24, but remained stable later in the maintenance period. With an increase in dose level, the improvement in efficacy was zero or minimal. This may be related to the vicious sulfonylurea cycle, in which a higher dosage leads to poor absorption of the drug and uncontrolled blood sugars.4. Again, hypoglycemic episodes increased by 3% to 7% (from week 8 to week 60) with random blood sugars below 60 mg/dl. Weight loss with SGLT2 was notable and showed a decline significant in BMI until week 24 and then stabilized during the maintenance period. On the other hand, the Sulfonylurea group had consistent weight gain at every point in the study. This was one of the major drawbacks of Sulfonyl... middle of paper... different mode of action, by which they controlled diabetes without stimulating the liver or pancreas. Glucose reabsorption was regulated using SGLT2 inhibitors, which reduced hypoglycemic episodes compared to the action of sulfonylurea. As a result of this new mode of action, future research may focus on the prevention of adverse effects (due to hypoglycemia) to various other organs of the body, weight and fat loss in severely obese type 2 diabetics, and maintenance long-term blood sugar levels. reduces complications of neuropathy, retinopathy, nephropathy, gangrene associated with chronic hyperglycemia 8. Long-term renal safety also needs to be evaluated in future research studies. Our study concluded that the SGLT2 inhibitor was effective and durable as an add-on therapy to metformin compared to combined metformin-sulfonylurea therapy.